Studying the Link Between Non-vitamin K Antagonist Oral Anticoagulants and Stroke Severity and Recovery Outcomes

What this Trial Is About

Researchers are studying the relationship between non-vitamin K antagonist oral anticoagulant NOAC therapy and the severity and outcomes of acute stroke in patients with atrial fibrillation. This observational study focuses on how NOAC adherence, dosage, and blood levels at the time of stroke affect stroke severity, short-term outcomes, and long-term stroke prevention. The study also examines the impact of starting or stopping antithrombotic therapy after a stroke on patients long-term health. The study involves collecting blood samples during acute stroke episodes to measure NOAC levels and recording stroke severity and 90-day functional outcomes. Patients are followed up for up to one year to track stroke outcomes while monitoring post-stroke antithrombotic treatments. Data from a national health insurance database will also be analyzed alongside a prospective patient cohort to understand these relationships more comprehensively. Participants will have their NOAC levels measured upon hospital arrival and will be assessed for stroke severity and functional recovery. Researchers will analyze primary outcomes including stroke occurrence and mortality up to 100 months, as well as safety outcomes such as major bleeding incidents. Consent and blood sample provision are required, and follow-up includes monitoring NOAC exposure and patient health over time.

The Association Between Non-vitamin K Antagonist Oral Anticoagulant Therapy and Acute Stroke Severity and Post Stroke Short-term and Long-term Outcomes.